{"nctId":"NCT00698932","briefTitle":"Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","startDateStruct":{"date":"2008-06"},"conditions":["Type 2 Diabetes"],"count":568,"armGroups":[{"label":"Saxagliptin 5mg","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with Type 2 diabetes\n* Patients should be drug naïve ie, not received medical treatment for diabetes,\n* HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)\n\nExclusion Criteria:\n\n* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes),\n* Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","description":"Adjusted\\* mean change from baseline in HbA1c achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. HbA1c data were excluded on and after rescue medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.15","spread":"0.050"},{"groupId":"OG001","value":"8.14","spread":"0.050"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":"0.063"},{"groupId":"OG001","value":"7.75","spread":"0.076"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"0.067"},{"groupId":"OG001","value":"-0.34","spread":"0.065"}]}]}]},{"type":"SECONDARY","title":"Absolute Change (mmol/L) From Baseline to Week 24 in Fasting Plasma Glucose (FPG)","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at week 24 (Last Observation Carried Forward (LOCF), Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.15","spread":"0.125"},{"groupId":"OG001","value":"9.05","spread":"0.141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.10","spread":"0.129"},{"groupId":"OG001","value":"8.77","spread":"0.163"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"0.144"},{"groupId":"OG001","value":"-0.17","spread":"0.141"}]}]}]},{"type":"SECONDARY","title":"Absolute Change (mg/dL) From Baseline to Week 24 in Fasting Plasma Glucose (FPG)","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164.85","spread":"2.253"},{"groupId":"OG001","value":"163.03","spread":"2.543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.97","spread":"2.317"},{"groupId":"OG001","value":"158.04","spread":"2.942"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.13","spread":"2.586"},{"groupId":"OG001","value":"-3.01","spread":"2.544"}]}]}]},{"type":"SECONDARY","title":"Absolute Change (mmol*Min/L) From Baseline to Week 24 in Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During Mixed Meal (Instant Noodles) Tolerance Tests (MMTT) in All MMTT Participants","description":"Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. Change from baseline for each subject is computed as the week 24 value minus the baseline value.PPG data were excluded on and after rescue medication","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2474","spread":"46.9"},{"groupId":"OG001","value":"2506","spread":"64.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2063","spread":"41.1"},{"groupId":"OG001","value":"2262","spread":"57.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-417","spread":"36.5"},{"groupId":"OG001","value":"-235","spread":"40.4"}]}]}]},{"type":"SECONDARY","title":"Absolute Change (mg*Min/dL) From Baseline to Week 24 in Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During Mixed Meal (Instant Noodles) Tolerance Tests (MMTT) in All MMTT Participants","description":"Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. Change from baseline for each subject is computed as the week 24 value minus the baseline value.PPG data were excluded on and after rescue medication","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44586","spread":"844.8"},{"groupId":"OG001","value":"45146","spread":"1170.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37166","spread":"739.6"},{"groupId":"OG001","value":"40751","spread":"1036.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7534","spread":"657.4"},{"groupId":"OG001","value":"-4255","spread":"726.4"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24","description":"Proportion of participants (expressed in percentage of total participants) achieving HbA1c \\< 7.0% for saxagliptin versus placebo at week 24. HbA1c Data were excluded on and after rescue medication","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":284},"commonTop":["Upper Respiratory Tract Infection"]}}}